Chemours Balansräkning Hälsa
Finansiell hälsa kriterier kontrolleras 0/6
Chemours har ett totalt eget kapital på $-48.0M och en total skuld på $3.8B vilket ger sin skuldsättningsgrad till -7985.4%. Dess totala tillgångar och totala skulder är $7.2B respektive $7.2B. Chemours s EBIT är $166.0M vilket gör dess räntetäckningsgrad 0.6. Den har kontanter och kortsiktiga investeringar på $671.0M.
Viktig information
-7,985.42%
Skuldsättning i förhållande till eget kapital
US$3.83b
Skuld
| Räntetäckningsgrad | 0.6x |
| Kontanter | US$671.00m |
| Eget kapital | -US$48.00m |
| Summa skulder | US$7.20b |
| Totala tillgångar | US$7.15b |
Nya uppdateringar om finansiell hälsa
Recent updates
Uppdatering av berättelse • Sep 17
CC: AI Cooling Exposure Will Support Earnings Upside Into 2026
Analysts have cut their price target on Chemours from $30 to $24, citing updated assumptions for discount rate, revenue growth, profit margins, and a higher future P/E outlook that together point to a lower fair value estimate. What's in the News for Chemours Chemours announced two new low global warming potential refrigerants, Opteon ZE and Opteon 515B, aimed at stationary chillers used in data centers and commercial buildings, addressing higher heat loads and uptime needs linked to AI and cloud infrastructure.
Uppdatering av berättelse • Sep 03
CC: PFAS Settlement And Legal Review Will Shape Cleaner Yet Cautious Outlook
Analysts have trimmed their price target on Chemours from $19.00 to $15.00 as they now model a higher discount rate, lower revenue growth, a reduced profit margin, and a higher future P/E multiple for the stock. What’s in the News for Chemours Pomerantz LLP announced an investigation into potential securities law violations at Chemours related to reduced adjusted EBITDA full year guidance and an oversupplied aftermarket channel, following which Chemours stock price fell significantly.
Uppdatering av berättelse • Aug 20
CC: Data Center Refrigerants And Regulatory Settlement Will Support Future Re Rating Potential
Analysts have reduced their price target on Chemours to $19.78 from $24.67 as they factor in updated assumptions for discount rate, revenue growth, profit margins, and future P/E multiples. What’s in the News for Chemours Chemours reported Q2 2026 results with net sales down 1% and adjusted EBITDA down 5%, citing volume pressure and operational costs, while emphasizing pricing actions, growth in higher value specialty solutions for data centers and semiconductors, and continued debt reduction and balance sheet work.Seeking Alpha • Aug 06
Chemours: Close To A 'Perfect' Rotation, With A 'Buy' In Q2 2026 (Rating Upgrade)
Summary Chemours is upgraded to 'BUY' with a $20 PT and $30 fair value, reflecting renewed upside after recent volatility. CC's recent rally was driven by sentiment, not fundamentals, but the company now shows improving liquidity, debt reduction, and solid EBITDA guidance. Risks remain from regulatory liabilities and elevated leverage, but CC's divestment plan and Opteon growth support a high-conviction turnaround thesis. At or below $15/share, CC offers 35-37% annual upside; at $20/share, the risk/reward remains attractive though more speculative. Read the full article on Seeking AlphaUppdatering av berättelse • Aug 05
CC: PFAS Settlement Will Support Cleaner Operations And Stronger Future Outlook
Analysts have trimmed their Chemours price target from $21.00 to $19.00 as updated assumptions point to different expectations for fair value, profitability, growth and future P/E levels. What’s in the News for Chemours Chemours announced a settlement with the U.S. Environmental Protection Agency and the West Virginia Department of Environmental Protection to resolve claims related to PFAS discharges and other alleged non compliance at its Washington Works, Fayetteville Works, and Chambers Works facilities.Uppdatering av berättelse • Jul 22
CC: Regulatory Settlement And Margin Recovery Will Drive Re Rating Potential
Analysts have lowered their price target on Chemours to $24.67 from $26.33, citing updated assumptions that include a slightly higher discount rate, modestly adjusted revenue growth expectations, a small change in projected profit margins, and a revised future P/E multiple. What’s in the News for Chemours BMO Capital reiterated a Buy rating on Chemours with a US$26 price target, which is close to the current median Wall Street target of US$25, according to recent analyst reports.Uppdatering av berättelse • Jul 06
CC: PFAS Settlement And Updated Outlook Will Shape Balanced Future Expectations
Analysts have raised their Chemours fair value estimate from $17.00 to $21.00, citing updated views on discount rate assumptions, revenue growth, profit margins and potential future P/E levels. What’s in the News for Chemours Chemours agreed to a multi-site PFAS settlement with the U.S. Environmental Protection Agency, the Department of Justice, the West Virginia Department of Environmental Protection, and multiple states, with total costs reported at more than US$450 million for penalties, mitigation projects, pollution controls, and community water initiatives.Uppdatering av berättelse • Jun 22
CC: Raised Margins And 2026 Outlook Will Support Further Earnings Upside
Analysts maintained their $30.00 price target on Chemours, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that together support keeping the prior valuation level. What’s in the News for Chemours Chemours issued earnings guidance for the second quarter of 2026, indicating an expected sequential change in consolidated net sales in a range of 15% to 20%, which the company links to seasonal trends.Uppdatering av berättelse • Jun 04
CC: Regulatory Reset And Margin Rebound Will Drive Re Rating Potential
Analysts now cite improved assumptions for Chemours' fair value, discount rate, revenue growth, profit margin, and future P/E in raising their price target by about $10 per share. What's in the News Chemours shares fell on May 21, 2026 after the EPA eased refrigerant regulations put in place during the Biden administration, according to recent news reports.Uppdatering av berättelse • May 15
CC: Cooling Alliance And 2026 Guidance Will Support Further Earnings Upside
Analysts have raised their price target for Chemours by $1 to $30, reflecting updated assumptions that include a slightly lower discount rate, modestly adjusted revenue growth expectations, a higher projected profit margin, and a reduced future P/E estimate. What's in the News Chemours issued earnings guidance for the second quarter of 2026, expecting consolidated net sales to be 15% to 20% higher sequentially, citing favorable seasonal trends (Corporate Guidance).Analysartikel • May 08
The Chemours Company Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts
It's been a mediocre week for The Chemours Company ( NYSE:CC ) shareholders, with the stock dropping 17% to US$22.41 in...Uppdatering av berättelse • Apr 22
CC: Cooling Partnership And 2026 Outlook Will Support Further Earnings Upside
Analysts now cite slightly higher long term revenue growth, profit margin, and P/E assumptions as reasons for raising Chemours fair value estimate from $25.00 to $29.00 per share. What's in the News Chemours and 2CRSi entered a Joint Development Agreement following the qualification of Chemours' Opteon two phase immersion cooling fluid in current generation 2CRSi servers, aimed at advancing two phase cooling technologies for high density IT infrastructure and AI workloads (Key Developments).Uppdatering av berättelse • Apr 08
CC: Share Repurchases And 2026 Outlook Will Support Earnings Upside
Analysts have raised their Chemours price target from $21.00 to $25.00, citing updated assumptions around revenue growth, profit margins, and a lower future P/E multiple as key drivers of the change. What's in the News Chemours completed its share repurchase program announced on May 2, 2022, buying back 10,342,722 shares (6.76%) for a total of $309.28 million, with no additional shares repurchased between October 1, 2025 and December 31, 2025 (Key Developments).Uppdatering av berättelse • Mar 24
CC: PFAS Litigation Will Drive Cautious Outlook Despite Cooling Technology Partnership
Analysts have maintained their $17.00 price target for Chemours, citing updated assumptions that include a 10.25% discount rate, 3.37% revenue growth, a 13.84% profit margin, and a future P/E of 3.87x, which they state continue to support the prior fair value view. What's in the News Chemours reported that between October 1, 2025 and December 31, 2025, it repurchased 0 shares for US$0 under its existing program and indicated that it has completed the buyback of 10,342,722 shares, or 6.76%, for US$309.28 million under the authorization announced on May 2, 2022 (Key Developments).Uppdatering av berättelse • Mar 09
CC: PFAS Legal Overhang And Cooling Partnership Will Shape Balanced Return Outlook
Analysts have raised their price target on Chemours from $13.00 to $17.00, citing updated assumptions around discount rate, revenue growth, profit margins, and future P/E that change their view of the company’s risk and earnings potential. What's in the News Chemours and 2CRSi entered a Joint Development Agreement after Chemours' Opteon two phase immersion cooling fluid was qualified in current generation 2CRSi servers, with a focus on advanced cooling for high density IT, AI, and next generation chips, and an emphasis on end user and environmental benefits.Uppdatering av berättelse • Feb 22
CC: Earnings Outlook And PFAS Legal Overhang Will Shape Future Upside
Analysts have revised their Chemours price target from $18.00 to $21.00, citing updated assumptions around discount rate, revenue growth, profit margin and future P/E that slightly adjust the risk and earnings profile they are using in their models. What's in the News Chemours issued new Full Year 2026 earnings guidance, with management indicating an expectation for Net Sales growth in the 3% to 5% range.Uppdatering av berättelse • Feb 08
CC: PFAS Class Action Risk Will Limit Future Shareholder Returns
Analysts have kept their Chemours fair value estimate steady at $13.00, with the latest price target grounded in unchanged fair value assumptions, along with updated views on discount rate, revenue growth, profit margin and future P/E levels. What's in the News On January 6, 2026, a Montana federal judge denied motions to dismiss a class action against DuPont/Chemours, 3M and several other gear and materials manufacturers related to alleged toxic PFAS chemicals in firefighter turnout gear.Analysartikel • Feb 03
The Chemours Company (NYSE:CC) Shares Fly 27% But Investors Aren't Buying For Growth
The The Chemours Company ( NYSE:CC ) share price has done very well over the last month, posting an excellent gain of...Uppdatering av berättelse • Jan 25
CC: Legal Overhang And Margin Reset Will Shape Balanced Outlook
Analysts have trimmed their price target on Chemours to about US$16 from roughly US$18, pointing to adjustments in profit margin expectations and valuation multiples, even though assumptions for revenue growth and future P/E have shifted. What's in the News A Montana federal judge denied motions to dismiss a class-action lawsuit involving PFAS in firefighter turnout gear, allowing claims against DuPont/Chemours and other manufacturers to move forward, including Racketeer Influenced Corrupt Organizations (RICO) claims that will remain active pending a related Ninth Circuit decision (Lawsuits & Legal Issues).Uppdatering av berättelse • Jan 11
CC: PFAS Lawsuit And Weaker Margins Will Restrain Future Shareholder Returns
Analysts have kept their Chemours fair value estimate steady at US$13.00. The latest price target update reflects adjusted assumptions around discount rate, revenue growth, profit margin and future P/E rather than a change in headline valuation.Uppdatering av berättelse • Dec 26
CC: Future Profitability Challenges Will Temper Benefits Of Completed Share Buybacks
Analysts have modestly raised their price target on Chemours to 13.00 dollars, reflecting slightly stronger revenue growth expectations and higher assumed future valuation multiples, while this is partially offset by a more cautious view on long term profitability and risk. What's in the News Completed a share repurchase program totaling 10,342,722 shares, representing 6.76% of outstanding shares, for $309.28 million under the buyback announced on May 2, 2022 (Key Developments).Uppdatering av berättelse • Dec 12
CC: Long-Term Margin Outlook Will Offset Near-Term Losses And Completed Buybacks
Analysts have raised their price target on Chemours from 11 dollars and 41 cents to 13 dollars, reflecting expectations for significantly stronger long term profit margins, despite slightly more conservative assumptions for revenue growth and valuation multiples. What's in the News Completed a share repurchase program totaling 10,342,722 shares, representing 6.76% of outstanding shares, for $309.28 million under the buyback announced on May 2, 2022 (Key Developments).Uppdatering av berättelse • Nov 01
CC: Global Supply Agreements And Buybacks Will Drive Undervalued Shares Higher
Analysts have adjusted their price target for Chemours. They are maintaining the fair value estimate at $17.78, but have slightly increased the discount rate and are projecting a modest decrease in both expected revenue growth and profit margin based on recent outlook factors.Uppdatering av berättelse • Oct 17
Low GWP Refrigerants And Advanced Materials Will Drive Future Success
Analysts have raised their price target for Chemours by $1.00, reflecting updated assumptions for modestly improved fair value and profit margin forecasts. What's in the News Chemours has entered into strategic agreements with SRF Limited to strengthen its global supply chain, enhance operational flexibility, and increase capacity for key materials such as fluoropolymers and fluoroelastomers (Key Developments).Uppdatering av berättelse • Oct 03
Low GWP Refrigerants And Advanced Materials Will Drive Future Success
Analysts have raised their price target for Chemours from $15.44 to $16.78, citing improved profit margins and slight increases in projected revenue growth as key factors for the update. What's in the News Chemours signed strategic agreements with SRF Limited to strengthen its global supply chain, increase operational flexibility, and secure fluoropolymer and fluoroelastomer capacity for multiple industries (Client Announcements).Uppdatering av berättelse • Sep 17
Low GWP Refrigerants And Advanced Materials Will Drive Future Success
The modest increase in Chemours’ Consensus Analyst Price Target reflects slightly higher forward P/E expectations, while the discount rate remains stable, resulting in a revised fair value of $15.44. What's in the News Chemours signed strategic agreements with SRF Limited to enhance global supply chain, increase operational flexibility, and access capacity for fluoropolymers and fluoroelastomers, with no upfront capital investment required.Analysartikel • Sep 03
The Chemours Company (NYSE:CC) Held Back By Insufficient Growth Even After Shares Climb 33%
The Chemours Company ( NYSE:CC ) shares have continued their recent momentum with a 33% gain in the last month alone...Analysartikel • Jul 26
Is It Time To Consider Buying The Chemours Company (NYSE:CC)?
The Chemours Company ( NYSE:CC ), is not the largest company out there, but it saw a significant share price rise of...Analysartikel • Jul 04
The Chemours Company's (NYSE:CC) Price Is Right But Growth Is Lacking After Shares Rocket 30%
The Chemours Company ( NYSE:CC ) shares have had a really impressive month, gaining 30% after a shaky period...Analysartikel • Jun 29
Chemours (NYSE:CC) Has No Shortage Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysartikel • May 14
We Like The Quality Of Chemours' (NYSE:CC) Earnings
Despite posting healthy earnings, The Chemours Company's ( NYSE:CC ) stock has been quite weak. Along with the solid...Analys av finansiell ställning
Kortfristiga skulder: CC har negativt eget kapital, vilket är en allvarligare situation än kortfristiga tillgångar som inte täcker kortfristiga skulder.
Långfristiga skulder: CC har negativt eget kapital, vilket är en allvarligare situation än kortfristiga tillgångar som inte täcker långfristiga skulder.
Skuld till eget kapital Historik och analys
Skuldnivå: CC har negativt eget kapital, vilket är en allvarligare situation än en hög skuldnivå.
Minska skulden: CC s har negativt eget kapital, så vi behöver inte kontrollera om dess skulder har minskat över tiden.
Skuldtäckning: CC s skuld är inte väl täckt av operativt kassaflöde ( 10.4% ).
Räntetäckning: CC s räntebetalningar på sin skuld är inte väl täckta av EBIT ( 0.6 x täckning).
Balansräkning
Upptäck friska företag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/09/20 20:26 |
| Aktiekurs vid dagens slut | 2026/09/18 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
The Chemours Company bevakas av 18 analytiker. 9 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| null null | Alembic Global Advisors |
| David Coleman | Argus Research Company |
| Michael Leithead | Barclays |